Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report

  • ID: 2228060
  • Report
  • Region: Global
  • 136 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc. (UK)
  • Merck & Co., Inc. (US)
  • Sanofi S.A. (France)
  • Symic Bio, Inc. (US)
  • TheraVasc Inc. (US)
  • MORE
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 23 companies including many key and niche players such as:
  • AstraZeneca Plc
  • Bayer HealthCare Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Proteon Therapeutics, Inc.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc. (UK)
  • Merck & Co., Inc. (US)
  • Sanofi S.A. (France)
  • Symic Bio, Inc. (US)
  • TheraVasc Inc. (US)
  • MORE

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
PAD
A Prelude
PAD Statistics
Table 1: Prevalence of Peripheral Artery Disease by Age Group and Gender (includes corresponding Graph/Chart)
Critical Limb Ischemia
An Insight
High Costs
A Cause of Concern

2. PAD THERAPEUTICS
Anti-Platelet Drugs: Spearheading the Battle against PAD
Key Drugs for Arterial Disease
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Vorapaxar (Zontivity)
Dual Antiplatelet Therapy (DAPT) for PAD
Entry of Generics Tones Down Growth in Major Markets
Brilinta Fails to Meet Expectations in EUCLID Trial
Xarelto Pins Hope on COMPASS and VOYAGER trials
Other Pipeline Drugs for Peripheral Arterial Disease (PAD)
Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal

3. MACRO GROWTH DRIVERS
Aging
A Key Driver
Table 2: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
Table 3: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
Table 4: Life Expectancy at Age 60 and 80 Years
(2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics
Table 5: Worldwide Prevalence of Diabetes: Number of Adults (20-79) with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart)
Table 6: Global Prevalence of Diabetes
Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2015 & 2040 (includes corresponding Graph/Chart)

4. PERIPHERAL ARTERIAL DISEASE (PAD)
AN OVERVIEW

5. COMPANIES INTO GENE THERAPY FOR PAD
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
CardioVascular BioTherapeutics, Inc. (US)
Celgene Corporation (US)
ID Pharma Co., Ltd. (Japan)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)

6. CLINICAL STUDIES/CORPORATE INITIATIVES
AstraZeneca Announces Results of EUCLID Trial
USPTO Extends Patent Term for Bayer’s Rivaroxaban
Bayer and Janssen Expand Clinical Development Programme for Rivaroxaban
FDA Approves Merck’s Zontivity

7. FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)

8. GLOBAL MARKET PERSPECTIVE
Table 8: World Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 9: World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 10: World 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
High PAD Incidence Drives Market
Table 11: Prevalence of Peripheral Arterial Disease by Age Group, Ethnicity, and Gender (2015)
Endovascular Intervention
A Review
Table 12: Volume Percentage Change in Interventional Procedures Performed in the US (2006-2014) (includes corresponding Graph/Chart)
Costs Associated with PAD Treatment
Generics Steal Market Share from Plavix
Aging Population Statistics & Diabetes Statistics: Key Opportunity Indicators
Table 13: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 14: Diabetes and Population Statistics in North America and Caribbean Region (2015 & 2040) (includes corresponding Graph/Chart)
Table 15: Diabetes Statistics in the US (2015)
Number of Adults with Diabetes (in 000s), Number of Adults with Undiagnosed Diabetes (in 000s), Diabetes Prevalence (%) and Number of Diabetes-Related Deaths (in ‘000s)
Clinical Studies/Product Approvals/Corporate Developments
Select Key Players
B.Market Analytics
Table 16: US Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: US Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA
A.Market Analysis
Measures to Increase PAD Awareness
B.Market Analytics
Table 18: Canadian Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 19: Canadian Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN
A.Market Analysis
Table 20: Aging Population in Japan (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Select Key Players
B.Market Analytics
Table 21: Japanese Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 22: Japanese Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE
A.Market Analysis
Plavix® Faces Generic and Branded Competition in Europe
B.Market Analytics
Table 23: European Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 24: European Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 25: European 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE
A.Market Analysis
Sanofi
A Leading French Player
B.Market Analytics
Table 26: French Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 27: French Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY
A.Market Analysis
Clinical Studies
Select Players
B.Market Analytics
Table 28: German Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 29: German Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY
Market Analysis
Table 30: Italian Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 31: Italian Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A.Market Analysis
Clinical Studies
AstraZeneca Plc: Key UK-Based Global Player
B.Market Analytics
Table 32: UK Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 33: UK Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN
Market Analysis
Table 34: Spanish Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 35: Spanish Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE
A.Market Analysis
Select Key Player
B.Market Analytics
Table 36: Rest of European Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 37: Rest of European Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
Market Analysis
Table 38: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 39: Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 40: Asia-Pacific 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for China and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5a. CHINA
Market Analysis
Table 41: Chinese Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 42: Chinese Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5b. REST OF ASIA-PACIFIC
A.Market Analysis
India
Key Player
B.Market Analytics
Table 43: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 44: Rest of Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. LATIN AMERICA
Market Analysis
Table 45: Latin American Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 46: Latin American Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

7. REST OF WORLD
A.Market Analysis
Current and Future Analysis
B.Market Analytics
Table 47: Rest of World Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 48: Rest of World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 23 (including Divisions/Subsidiaries 25)

  • The United States (9)
  • Canada (1)
  • Japan (2)
  • Europe (7)
    • France (1)
    • Germany (2)
    • The United Kingdom (1)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (6)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca Plc. (UK)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Bristol-Myers Squibb Company (US)
  • Merck & Co., Inc. (US)
  • Proteon Therapeutics, Inc. (US)
  • Sanofi S.A. (France)
  • Symic Bio, Inc. (US)
  • TheraVasc Inc. (US)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll